Boops Pets Launches Clinical Grade KSM 66 Ashwagandha Canine Calming Chews
Boops Pets introduces NASC audited canine calming chews featuring clinical grade KSM 66 Ashwagandha. These supplements address pet anxiety with quality assurance. NASC auditing ensures manufacturing standards but not clinical efficacy.
Medicinal Cannabis Demand for Mental Health Soars, Evidence Lags – Monash Lens
Medicinal cannabis mental health demand is rapidly increasing, especially for anxiety and PTSD. However, clinical evidence supporting its use remains limited. This gap creates challenges for healthcare providers balancing patient needs and treatment…
For College Graduates, the Job Market Is Looking More and More Bleak – SFGATE
Economic stress and unemployment young adults face are linked to increased cannabis use as a coping strategy. This focus keyword highlights the challenges college graduates encounter in today's job market. Understanding these factors helps clinicians…
As Cannabis Use Rises, Mental Health Risk Factors Increase
Rising cannabis use patterns require clinicians to assess cannabis mental health risk factors systematically. The relationship between cannabis use and psychiatric symptoms is complex and bidirectional. Understanding these risk factors is essential for…
8 Behavioral Health Studies to Know for Cannabis Research
Behavioral health cannabis research is critical for understanding medical cannabis applications in anxiety, PTSD, and depression. This article reviews 8 key studies shaping clinical perspectives. Knowing these studies helps clinicians evaluate evidence…
Cannabis Provides Help For Patients With Chronic Pain, Anxiety, and Depression
Cannabis chronic pain anxiety depression evidence highlights its potential benefits for patients. Clinical trials support cannabis use for neuropathic pain, while anxiety and depression require cautious approaches. Understanding this evidence helps guide…
Medicinal CBD Varieties 15-25% CBD Low THC – Seeds Genetics Co.
Medicinal CBD varieties with 15-25% CBD and low THC offer therapeutic potential for anxiety, epilepsy, and inflammation. These cultivars provide clinical relevance without intoxication. Understanding dosing and product quality is key for effective use.
The Madness of Using Cannabis to Treat Mental Health | The Spectator
Cannabis mental health risk assessment is critical for clinicians addressing patient questions about cannabis use in psychiatric conditions. Evidence shows mixed outcomes depending on diagnosis and formulation. Careful evaluation helps balance potential…
The unsettling truth about medical cannabis and mental health
Medical cannabis mental health challenges require careful clinical consideration. Understanding both therapeutic potential and psychiatric risks is essential for safe prescribing. Cannabis can offer symptom relief but may also exacerbate certain mental…
New York Approves Cannabis for Anxiety: Clinical Evidence Review
Cannabis for anxiety disorders is a growing topic in medical cannabis policy. Current clinical evidence remains mixed, with some studies showing limited benefits. Patients and clinicians should carefully consider the risks and monitor outcomes.
